# US 2019/0167757 A1 · Compounds and methods for increasing hair growth > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167757 A1 - Document ID: US20190167757A1 - Status: Published application - Kind: A1 - Application number: 16/275,069 - Filed: 2019-02-13 - Published: 2019-06-06 - Earliest claimed: 2014-01-23 - Assignees: University of Kansas - Applicants: The University of Kansas - Inventors: Peter S. N. Rowe; Aline Martin; Nicolae Valentin David; M. Laird Forrest; Kenneth Ryan Moulder; Shuang Cai; Daniel J. Aires - Web page: https://patentgrep.com/patent/US20190167757A1 ## CPC - A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} - A61K 8/14: Liposomes; Vesicles - A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)} - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 31/506: not condensed and containing further heterocyclic rings - A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/6911: {the form being a liposome} - A61P 17/00: Drugs for dermatological disorders - A61Q 7/00: Preparations for affecting hair growth - A61K 2800/412: Microsized, i.e. having sizes between 0.1 and 100 microns - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS ## Abstract A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject. ## Claims ### Claim at position 1 -20. (canceled) ### Claim 21 A method of promoting hair growth, the method comprising: providing a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4, wherein SPR4 is: TVNAFYSASTNYPRSLSYGAIGVIVGHEFTHGFDNNGRGENIADNG (SEQ ID NO: 21); and topically administering the polypeptide to a subject. ### Claim 22 (depends on 21) The method of claim 21, comprising providing a composition having a pharmaceutical carrier configured for topical application to a subject having the polypeptide; and administering the composition topically so as to administer the polypeptide to the subject. ### Claim 23 (depends on 21) The method of claim 21, comprising administering the polypeptide to: skin of the subject: a hair follicle of the subject or a bald spot of the subject. ### Claim 24 (canceled) ### Claim 25 (canceled) ### Claim 26 (depends on 21) The method of claim 21, comprising administering the polypeptide so as to: modulate the Wnt/beta-catenin canonical pathway; regulate one or more genes involved in hair growth; accelerate hair growth; lengthen the anagen phase; reduce 5-alpha-reductase; suppress sclerostin; and/or increase active beta-catenin. ### Claim 27 (canceled) ### Claim 28 (canceled) ### Claim 29 (canceled) ### Claim 30 (canceled) ### Claim 31 (canceled) ### Claim 32 (canceled) ### Claim 33 (canceled) ### Claim 34 (depends on 21) The method of claim 21, comprising administering the polypeptide in an amount to: treat alopecia and/or related syndromes; lengthen the anagen phase; increase hair growth on a bald spot and/or increase hair follicle growth. ### Claim 35 (canceled) ### Claim 36 (canceled) ### Claim 37 (canceled) ### Claim 38 (depends on 21) The method of claim 21, comprising administering the polypeptide in an amount to increase hair growth compared to when the polypeptide is not administered. ### Claim 39 (depends on 21) The method of claim 21, comprising administering the polypeptide by micro-needle injection. ### Claim 40 (depends on 39) The method of claim 39, wherein the micro-needle injection is performed by a derma-roller. ### Claim 41 (depends on 39) The method of claim 39, wherein the skin is not visibly damaged by the micro-needle injection. ### Claim 42 (depends on 39) The method of claim 39, comprising forming micro-pores in the skin with the micro-needle, and allowing the micro-pores to close after the micro-needle injection. ### Claim 43 (depends on 22) The method of claim 22, wherein the pharmaceutical carrier is a liposome. ### Claim 44 (depends on 21) The method of claim 21, wherein the polypeptide is included in a fusion polypeptide with a second polypeptide, wherein the second polypeptide includes an endosomal disrupting polypeptide. ### Claim 45 (depends on 22) The method of claim 22, wherein the SPR4 is dissolved in the pharmaceutical carrier selected from one or more of cetearyl alcohol, cetearyl glucoside, squalane, isopropyl palmate, octyldodecaonol, phenoxyethanol, methylparaben, etheylparaben, butylparaben, propylparaben, isobutylparaben, glycerin, butylene glycol, sodium acrylate, acryloyldimethyl taurate, isohexadecane, polysorbate, glyceryl stearate, dicaprylyl ether, alkyl benzoate, isononyl isononanoate, methylpropanediol, iodoproynyl butylcarbamate, triethanolamine, ketoconazole, serenoa serrulata extract, emu oil, niacin vitamin B3, caffeine, pyridoxine, L-pathenol, linolenic acid, simmondsia chinesis seed oil, zinc oxide, lecithin, ZnCb, L-α-phosphatidylcholine, ethanol, PBS, phospholipids, fatty acids, tocopherol, and derivatives thereof and equivalents thereof. ### Claim 46 (depends on 21) The method of claim 21, further comprising administering an active hair growth agent selected from minoxidil and finasteride. ### Claim 47 (depends on 22) The method of claim 22, wherein the pharmaceutical carrier is a micro emulsion or a nano emulsion. ### Claim 48 (depends on 22) The method of claim 22, wherein the pharmaceutical carrier contains ZnCl2. ### Claim 49 (depends on 22) The method of claim 22, wherein the SPR4 is present at about 41% w/w in the composition, which is configured for topical delivery. ### Claim 50 (depends on 22) The method of claim 22, wherein the SPR4 is present at about 0.98-1 mg/ml in the topical composition. ### Claim 51 (depends on 22) The method of claim 22, wherein the carrier includes about 50 mg/ml to about 104 mg/ml lipid. ### Claim 52 (depends on 22) The method of claim 22, wherein the pharmaceutical carrier includes a lipid and ethanol.